FDA approves Roche’s Wilserdly for advanced breast cancer

The FDA approved Roche’s Wilserdly, or giredestrant, with Novartis’s Afinitor for certain advanced or metastatic breast cancers. The Phase 3 evidence cited for the approval showed a 62% reduction in disease progression or death. Roche is awaiting a separate FDA decision on earlier-stage use and expects peak annual sales of more than 3 billion Swiss francs.

The approval lets Roche commercialize Wilserdly in the authorized advanced-breast-cancer population, while a decision on earlier-stage use could expand its reach. Vontobel’s note says the approval strengthens Roche’s growth outlook, although AstraZeneca and Eli Lilly are developing competing treatments.

  • 1The FDA authorized Wilserdly in combination with Novartis’s Afinitor for advanced or metastatic breast cancer, marking the drug’s first U.S. approval.
  • 2The Phase 3 trial cited for the approval showed a 62% reduction in disease progression or death.
  • 3Roche has guided for more than 3 billion Swiss francs ($3.57 billion) in peak annual sales for Wilserdly.
  • 4Roche is awaiting a separate FDA decision on Wilserdly for earlier-stage breast cancer.
  • Material 1 specifies HR-positive, HER2-negative disease with an ESR1 gene mutation, while the other materials do not provide all of those indication qualifiers.

Sources